Sarepta Therapeutics faces heightened scrutiny after reporting a second patient death linked to its gene therapy Elevidys for Duchenne muscular dystrophy (DMD). Both fatalities involved acute liver failure in teenage boys receiving high therapy doses. The company has paused shipments to older, non-ambulatory patients and is collaborating with FDA to implement enhanced immune-suppressive protocols. These developments have significantly impacted Sarepta's stock and raised concerns within the patient community regarding the therapy's safety profile following its accelerated FDA approval.